ADMA Biologics to Announce Q3 2024 Financial Results on November 7, 2024

ADMA Biologics, Inc. (Nasdaq: ADMA) disclosed that it will announce its financial results for the third quarter of 2024 on November 7, 2024, after the closing of the U.S. financial markets. Following this announcement, the company's management team will conduct a live conference call and audio webcast at 4:30 p.m. ET to discuss the financial outcomes and other updates related to the company. Interested parties can join the conference call by dialing (888) 596-4144 and using the conference ID 2959956. It is recommended to join the call approximately 10 minutes before it begins, although participants can join at any time during the call. Those who do not plan to ask questions during the call are encouraged to listen to the live webcast available on the company's website under the "Events & Webcasts" section. An archived replay of the event will also be accessible on the same website.

ADMA Biologics is a comprehensive commercial biopharmaceutical company that focuses on the manufacture, marketing, and development of specialty biologics. Their products aim to treat immunodeficient patients who are at risk of infections and other individuals vulnerable to specific infectious diseases. The company currently produces and markets three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB®. BIVIGAM® is used to treat primary humoral immunodeficiency (PI). ASCENIV™ also treats PI, while NABI-HB® is used to enhance immunity against the hepatitis B virus.

The manufacturing of these immune globulin products takes place at ADMA's FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida. Additionally, through its subsidiary ADMA BioCenters, the company operates as an FDA-approved source plasma collector in the United States, providing the essential blood plasma for its products.

The mission of ADMA Biologics is to produce, market, and develop specialty biologics and human immune globulins tailored for specific patient groups. These products are designed for the treatment and prevention of certain infectious diseases and for managing immune-compromised patients who suffer from an underlying immune deficiency or are immune compromised due to other medical conditions. The company holds numerous patents in the United States and abroad that cover various aspects of its products and product candidates. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!